A selective inhibitor of p38α and p38β MAP kinase
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SD 169

Item No. 14156

Technical Information
Formal Name
1H-indole-5-carboxamide
CAS Number
1670-87-7
Synonyms
  • 5-Carbamoylindole
Molecular Formula
C9H8N2O
Formula Weight
Purity
≥97%
A crystalline solid
DMF: 16 mg/mlDMF:PBS(pH 7.2)(1:1): 0.5 mg/mlDMSO: 5 mg/mlEthanol: 1.4 mg/ml
λmax
237, 276 nm
SMILES
NC(C1=CC=C(NC=C2)C2=C1)=O
InChi Code
InChI=1S/C9H8N2O/c10-9(12)7-1-2-8-6(5-7)3-4-11-8/h1-5,11H,(H2,10,12)
InChi Key
GQMYQEAXTITUAE-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    SD 169 is a selective ATP competitive inhibitor of the MAP kinases p38α (IC50 = 3.2 nM) and p38β (IC50 = 122 nM).1 It has no inhibitory effect against a panel of other kinases, including p38γ MAP kinase, ERK2, JNK-1, and MAPKAPK-2, when tested in vitro at 50 μM.1 SD 169 is orally active, significantly reducing p38 MAP kinase expression in T cells of nonobese diabetic mice when delivered in chow at 600 mg/kg.1 In this model, SD 169 also reduced the incidence of diabetes, lowered blood glucose, and improved glucose homeostasis.1 SD 169 also enhances axonal regeneration after sciatic nerve crush injury in rats, when given by gavage (30 mg/kg) before and after nerve damage.2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Medicherla, S., Protter, A.A., Ma, J.Y., et al. Preventive and therapeutic potential of p38α-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J. Pharmacol. Exp. Ther. 318(1), 99-107 (2006).

    2. Myers, R.R., Sekiguchi, Y., Kikuchi, S., et al. Inhibition of p38 MAP kinase activity enhances axonal regeneration. Exp. Neurol. 184(2), 606-614 (2003).